Principles of a new treatment algorithm in multiple sclerosis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Principles of a new treatment algorithm in multiple sclerosis. / Hartung, Hans-Peter; Montalban, Xavier; Sorensen, Per Soelberg; Vermersch, Patrick; Olsson, Tomas.

I: Expert Review of Neurotherapeutics, Bind 11, Nr. 3, 2011, s. 351-62.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Hartung, H-P, Montalban, X, Sorensen, PS, Vermersch, P & Olsson, T 2011, 'Principles of a new treatment algorithm in multiple sclerosis', Expert Review of Neurotherapeutics, bind 11, nr. 3, s. 351-62. https://doi.org/10.1586/ern.11.15

APA

Hartung, H-P., Montalban, X., Sorensen, P. S., Vermersch, P., & Olsson, T. (2011). Principles of a new treatment algorithm in multiple sclerosis. Expert Review of Neurotherapeutics, 11(3), 351-62. https://doi.org/10.1586/ern.11.15

Vancouver

Hartung H-P, Montalban X, Sorensen PS, Vermersch P, Olsson T. Principles of a new treatment algorithm in multiple sclerosis. Expert Review of Neurotherapeutics. 2011;11(3):351-62. https://doi.org/10.1586/ern.11.15

Author

Hartung, Hans-Peter ; Montalban, Xavier ; Sorensen, Per Soelberg ; Vermersch, Patrick ; Olsson, Tomas. / Principles of a new treatment algorithm in multiple sclerosis. I: Expert Review of Neurotherapeutics. 2011 ; Bind 11, Nr. 3. s. 351-62.

Bibtex

@article{f09bac5a4c0a4d2e86fc57b101e1c18c,
title = "Principles of a new treatment algorithm in multiple sclerosis",
abstract = "We are entering a new era in the management of patients with multiple sclerosis (MS). The first oral treatment (fingolimod) has now gained US FDA approval, addressing an unmet need for patients with MS who wish to avoid parenteral administration. A second agent (cladribine) is currently being considered for approval. With the arrival of these oral agents, a key question is where they may fit into the existing MS treatment algorithm. This article aims to help answer this question by analyzing the trial data for the new oral therapies, as well as for existing MS treatments, by applying practical clinical experience, and through consideration of our increased understanding of how to define treatment success in MS. This article also provides a speculative look at what the treatment algorithm may look like in 5 years, with the availability of new data, greater experience and, potentially, other novel agents.",
author = "Hans-Peter Hartung and Xavier Montalban and Sorensen, {Per Soelberg} and Patrick Vermersch and Tomas Olsson",
year = "2011",
doi = "http://dx.doi.org/10.1586/ern.11.15",
language = "English",
volume = "11",
pages = "351--62",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Taylor & Francis",
number = "3",

}

RIS

TY - JOUR

T1 - Principles of a new treatment algorithm in multiple sclerosis

AU - Hartung, Hans-Peter

AU - Montalban, Xavier

AU - Sorensen, Per Soelberg

AU - Vermersch, Patrick

AU - Olsson, Tomas

PY - 2011

Y1 - 2011

N2 - We are entering a new era in the management of patients with multiple sclerosis (MS). The first oral treatment (fingolimod) has now gained US FDA approval, addressing an unmet need for patients with MS who wish to avoid parenteral administration. A second agent (cladribine) is currently being considered for approval. With the arrival of these oral agents, a key question is where they may fit into the existing MS treatment algorithm. This article aims to help answer this question by analyzing the trial data for the new oral therapies, as well as for existing MS treatments, by applying practical clinical experience, and through consideration of our increased understanding of how to define treatment success in MS. This article also provides a speculative look at what the treatment algorithm may look like in 5 years, with the availability of new data, greater experience and, potentially, other novel agents.

AB - We are entering a new era in the management of patients with multiple sclerosis (MS). The first oral treatment (fingolimod) has now gained US FDA approval, addressing an unmet need for patients with MS who wish to avoid parenteral administration. A second agent (cladribine) is currently being considered for approval. With the arrival of these oral agents, a key question is where they may fit into the existing MS treatment algorithm. This article aims to help answer this question by analyzing the trial data for the new oral therapies, as well as for existing MS treatments, by applying practical clinical experience, and through consideration of our increased understanding of how to define treatment success in MS. This article also provides a speculative look at what the treatment algorithm may look like in 5 years, with the availability of new data, greater experience and, potentially, other novel agents.

U2 - http://dx.doi.org/10.1586/ern.11.15

DO - http://dx.doi.org/10.1586/ern.11.15

M3 - Journal article

VL - 11

SP - 351

EP - 362

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 3

ER -

ID: 40198071